We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UNH Q3 Earnings Call Highlights 2027 Growth and Margin Recovery
Read MoreHide Full Article
Key Takeaways
UnitedHealth raises 2026 adjusted EPS guidance to at least $20.50, targeting renewed earnings growth in 2027.
Elevated commercial medical costs and Medicaid funding gaps remain hurdles despite stabilizing cost trends.
Optum Health's earnings rebound and AI expansion support recovery.
UnitedHealth Group Incorporated (UNH - Free Report) outlined improving operating momentum during its third-quarter 2026 earnings call, emphasizing disciplined medical cost management, business modernization and a return to sustainable earnings growth in 2027.
Management raised its full-year earnings outlook while acknowledging persistent commercial medical cost pressures, uneven Medicaid funding and continued investments across Optum.
UNH Raises Outlook and Signals 2027 Growth
Chief financial officer Wayne DeVeydt raised the 2026 adjusted earnings guidance to at least $20.50 per share, establishing a stronger earnings base heading into 2027.
DeVeydt said the lower end of UnitedHealth's long-term 13%-16% earnings growth target represents a reasonable starting point for 2027, with current analyst consensus potentially understating the opportunity.
Third-quarter adjusted earnings of $4.69 per share exceeded the Zacks Consensus Estimate of $4.12. Revenues of $112.69 billion surpassed the consensus estimate of $111.38 billion.
UnitedHealth Group Incorporated Price, Consensus and EPS Surprise
UnitedHealthcare CEO Timothy Noel emphasized that commercial medical cost trends remain above the company's initial 11% expectations, reflecting specialty drug expenses, higher clinician costs and No Surprises Act arbitration pressures.
During questioning from UBS, Noel acknowledged that elevated utilization would extend the timeline for achieving long-term commercial margin objectives.
Responding to Bank of America, Noel clarified that management was not seeing medical costs accelerate. Instead, commercial trends were stabilizing, while government programs showed moderation.
UNH Targets Medicare and Medicaid Margin Recovery
Bobby Hunter, CEO of Government Programs and Head of Medicare Insurance, told Wolfe Research that Medicare margins should finish 2026 near the upper end of the company's 2%-4% target range.
For 2027, Hunter highlighted growth opportunities in Dual Special Needs Plans, Chronic Special Needs Plans and high-value HMOs. Management continues refining its Medicare Advantage product portfolio while maintaining pricing discipline.
Medicaid CEO Michael Cotton said full-year core Medicaid margins should improve to moderately better than negative 1%. He identified clinical cost management and state funding adjustments as recovery drivers, with a goal of returning to target margins by 2028.
UnitedHealth Advances Optum Health Turnaround
Optum Health generated third-quarter operating earnings of $735 million compared with $41 million a year earlier, reflecting improved medical cost management and operational discipline.
Optum Health CEO Krista Nelson highlighted opportunities in accountable care, home health, hospice and post-acute services. The business remains focused on progressing toward its 6%-8% operating margin target by 2028.
Responding to Barclays, Nelson explained that fourth-quarter performance would reflect normal risk seasonality and additional technology investments. She emphasized that operational improvements achieved during 2026 should continue supporting performance.
UNH Expands Pharmacy and AI Opportunities
Optum CEO Patrick Conway emphasized integrating pharmacy services with medical care, including specialty pharmacy, behavioral health pharmacy and infusion services.
During JPMorgan's questioning, Chief Growth Officer Jon Mahrt reported specialty pharmacy volume growth of 2.6% despite a broader quarterly volume decline. He also highlighted customer retention in the high 90s within pharmacy benefit management.
Chief Digital and Technology Officer Sandeep Dadlani described Optum Insight's multiyear AI transformation. Its Integrity One platform expanded from two implemented clients at year-end 2025 to 15, with another 24 implementations underway.
UnitedHealth Prioritizes Sustainable Execution
CEO Stephen Hemsley emphasized restoring financial discipline, simplifying healthcare administration and strengthening relationships with clinicians and consumers.
The company expects AI-enabled processes, integrated value-based care and operational modernization to support productivity and service improvements while positioning its businesses for sustainable growth.
Management plans to provide a more comprehensive 2027 outlook before year-end, including additional clarity on business-level opportunities and investments.
The stock has a Value Score of A, Growth Score of A, Momentum Score of B and a VGM Score of A. These favorable Style Scores complement its Zacks Rank, reflecting attractive characteristics across valuation, growth and momentum factors.
The combination of a Zacks Rank #2 and strong Style Scores aligns with Zacks' framework for identifying stocks with favorable relative performance potential. However, the Zacks Rank can change as analysts revise earnings estimates following the recently reported results.
View the Zacks #1 Rank List
Image: Bigstock
UNH Q3 Earnings Call Highlights 2027 Growth and Margin Recovery
Key Takeaways
UnitedHealth Group Incorporated (UNH - Free Report) outlined improving operating momentum during its third-quarter 2026 earnings call, emphasizing disciplined medical cost management, business modernization and a return to sustainable earnings growth in 2027.
Management raised its full-year earnings outlook while acknowledging persistent commercial medical cost pressures, uneven Medicaid funding and continued investments across Optum.
UNH Raises Outlook and Signals 2027 Growth
Chief financial officer Wayne DeVeydt raised the 2026 adjusted earnings guidance to at least $20.50 per share, establishing a stronger earnings base heading into 2027.
DeVeydt said the lower end of UnitedHealth's long-term 13%-16% earnings growth target represents a reasonable starting point for 2027, with current analyst consensus potentially understating the opportunity.
Third-quarter adjusted earnings of $4.69 per share exceeded the Zacks Consensus Estimate of $4.12. Revenues of $112.69 billion surpassed the consensus estimate of $111.38 billion.
UnitedHealth Group Incorporated Price, Consensus and EPS Surprise
UnitedHealth Group Incorporated price-consensus-eps-surprise-chart | UnitedHealth Group Incorporated Quote
UnitedHealth Faces Elevated Commercial Costs
UnitedHealthcare CEO Timothy Noel emphasized that commercial medical cost trends remain above the company's initial 11% expectations, reflecting specialty drug expenses, higher clinician costs and No Surprises Act arbitration pressures.
During questioning from UBS, Noel acknowledged that elevated utilization would extend the timeline for achieving long-term commercial margin objectives.
Responding to Bank of America, Noel clarified that management was not seeing medical costs accelerate. Instead, commercial trends were stabilizing, while government programs showed moderation.
UNH Targets Medicare and Medicaid Margin Recovery
Bobby Hunter, CEO of Government Programs and Head of Medicare Insurance, told Wolfe Research that Medicare margins should finish 2026 near the upper end of the company's 2%-4% target range.
For 2027, Hunter highlighted growth opportunities in Dual Special Needs Plans, Chronic Special Needs Plans and high-value HMOs. Management continues refining its Medicare Advantage product portfolio while maintaining pricing discipline.
Medicaid CEO Michael Cotton said full-year core Medicaid margins should improve to moderately better than negative 1%. He identified clinical cost management and state funding adjustments as recovery drivers, with a goal of returning to target margins by 2028.
UnitedHealth Advances Optum Health Turnaround
Optum Health generated third-quarter operating earnings of $735 million compared with $41 million a year earlier, reflecting improved medical cost management and operational discipline.
Optum Health CEO Krista Nelson highlighted opportunities in accountable care, home health, hospice and post-acute services. The business remains focused on progressing toward its 6%-8% operating margin target by 2028.
Responding to Barclays, Nelson explained that fourth-quarter performance would reflect normal risk seasonality and additional technology investments. She emphasized that operational improvements achieved during 2026 should continue supporting performance.
UNH Expands Pharmacy and AI Opportunities
Optum CEO Patrick Conway emphasized integrating pharmacy services with medical care, including specialty pharmacy, behavioral health pharmacy and infusion services.
During JPMorgan's questioning, Chief Growth Officer Jon Mahrt reported specialty pharmacy volume growth of 2.6% despite a broader quarterly volume decline. He also highlighted customer retention in the high 90s within pharmacy benefit management.
Chief Digital and Technology Officer Sandeep Dadlani described Optum Insight's multiyear AI transformation. Its Integrity One platform expanded from two implemented clients at year-end 2025 to 15, with another 24 implementations underway.
UnitedHealth Prioritizes Sustainable Execution
CEO Stephen Hemsley emphasized restoring financial discipline, simplifying healthcare administration and strengthening relationships with clinicians and consumers.
The company expects AI-enabled processes, integrated value-based care and operational modernization to support productivity and service improvements while positioning its businesses for sustainable growth.
Management plans to provide a more comprehensive 2027 outlook before year-end, including additional clarity on business-level opportunities and investments.
UNH's Zacks Rank and Style Scores Signal
UNH currently carries a Zacks Rank #2 (Buy), indicating favorable near-term prospects based on earnings estimate revision trends. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The stock has a Value Score of A, Growth Score of A, Momentum Score of B and a VGM Score of A. These favorable Style Scores complement its Zacks Rank, reflecting attractive characteristics across valuation, growth and momentum factors.
The combination of a Zacks Rank #2 and strong Style Scores aligns with Zacks' framework for identifying stocks with favorable relative performance potential. However, the Zacks Rank can change as analysts revise earnings estimates following the recently reported results.